Interleukin-6 and melanoma

被引:73
作者
Hoejberg, Lise [1 ,2 ]
Bastholt, Lars [1 ]
Schmidt, Henrik [3 ]
机构
[1] Odense Univ Hosp, Dept Oncol, DK-5000 Odense C, Denmark
[2] Univ So Denmark, Inst Clin Res, Odense, Denmark
[3] Aarhus Univ Hosp, Dept Oncol, DK-8000 Aarhus, Denmark
关键词
biomarker; interleukin-6; melanoma; C-REACTIVE PROTEIN; SERUM INTERLEUKIN-6; CIRCULATING INTERLEUKIN-6; LEVELS CORRELATE; RHEUMATOID-ARTHRITIS; PROGNOSTIC-FACTOR; GROWTH INHIBITOR; CANCER; RECEPTOR; TUMOR;
D O I
10.1097/CMR.0b013e3283543d72
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Interleukin-6 (IL-6) is a pleiotropic immunomodulatory cytokine produced by various types of cells, including melanoma cells. IL-6 plays a major role in the pathogenesis and development of malignancies. It promotes tumour growth by inhibition of apoptosis and induces tumour angiogenesis. IL-6 is deregulated in many types of cancers, and increased serum concentration of IL-6 has been correlated with a worse prognosis in patients with different cancers, including melanoma. Several serum cytokines including IL-6 play an important role in the development and progression of melanoma; however, the specific biological functions of IL-6 in progression of melanoma are unknown. In 1:his review, we present studies on cell cultures and mouse models and summarize published clinical studies on IL-6 and melanoma. Melanoma Res 22:327-333 (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
引用
收藏
页码:327 / 333
页数:7
相关论文
共 77 条
[1]   Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer - Modern target but ancient solution [J].
Aggarwal, Bharat B. ;
Sethi, Gautam ;
Ahn, Kwang Seok ;
Sandur, Santosh K. ;
Pandey, Manoj K. ;
Kunnumakkara, Ajaikumar B. ;
Sung, Bokyung ;
Ichikawa, Haruyo .
SIGNAL TRANSDUCTION PATHWAYS, PT B: STRESS SIGNALING AND TRANSCRIPTIONAL CONTROL, 2006, 1091 :151-169
[2]   RECOMBINANT HUMAN B-CELL STIMULATORY FACTOR-II (BSF-2/IFN-BETA2) REGULATES BETA-FIBRINOGEN AND ALBUMIN MESSENGER-RNA LEVELS IN FAO-9 CELLS [J].
ANDUS, T ;
GEIGER, T ;
HIRANO, T ;
NORTHOFF, H ;
GANTER, U ;
BAUER, J ;
KISHIMOTO, T ;
HEINRICH, PC .
FEBS LETTERS, 1987, 221 (01) :18-22
[3]  
Argiles J M, 1998, Curr Opin Clin Nutr Metab Care, V1, P245, DOI 10.1097/00075197-199805000-00002
[4]   Interleukin-6: From identification of the cytokine to development of targeted treatments [J].
Assier, Eric ;
Boissier, Marie-Christophe ;
Dayer, Jean-Michel .
JOINT BONE SPINE, 2010, 77 (06) :532-536
[5]   BIOLOGIC EFFECTS OF ANTI-INTERLEUKIN-6 MURINE MONOCLONAL-ANTIBODY IN ADVANCED MULTIPLE-MYELOMA [J].
BATAILLE, R ;
BARLOGIE, B ;
LU, ZY ;
ROSSI, JF ;
LAVABREBERTRAND, T ;
BECK, T ;
WIJDENES, J ;
BROCHIER, J ;
KLEIN, B .
BLOOD, 1995, 86 (02) :685-691
[6]   SERUM INTERLEUKIN-6 LEVELS CORRELATE WITH DISEASE STATUS IN PATIENTS WITH EPITHELIAL OVARIAN-CANCER [J].
BEREK, JS ;
CHUNG, C ;
KALDI, K ;
WATSON, JM ;
KNOX, RM ;
MARTINEZMAZA, O .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1991, 164 (04) :1038-1043
[7]  
Bíró L, 1998, EUR J CLIN INVEST, V28, P679
[8]  
BLAY JY, 1992, CANCER RES, V52, P3317
[9]   INTERLEUKIN-6 IS THE MAJOR REGULATOR OF ACUTE PHASE PROTEIN-SYNTHESIS IN ADULT HUMAN HEPATOCYTES [J].
CASTELL, JV ;
GOMEZLECHON, MJ ;
DAVID, M ;
ANDUS, T ;
GEIGER, T ;
TRULLENQUE, R ;
FABRA, R ;
HEINRICH, PC .
FEBS LETTERS, 1989, 242 (02) :237-239
[10]   The soluble Interleukin 6 receptor: Generation and role in inflammation and cancer [J].
Chalaris, Athena ;
Garbers, Christoph ;
Rabe, Bjoern ;
Rose-John, Stefan ;
Scheller, Juergen .
EUROPEAN JOURNAL OF CELL BIOLOGY, 2011, 90 (6-7) :484-494